Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRC0202
- Development stage
- Phase 2
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HRC0202 is a fully human, anti-BCMA (B-cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy developed for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM), including those who have relapsed after prior anti-BCMA therapy. It utilizes a second-generation CAR construct, incorporating a single-chain variable fragment (scFv) derived from a fully human anti-BCMA antibody (HK10), combined with a 4-1BB (CD137) costimulatory domain and a CD3-zeta (CD3ζ) signaling domain, delivered via retroviral vector. The product is manufactured from autologous T cells, transduced and expanded ex vivo, then infused intravenously after lymphodepleting chemotherapy.[1][2][5]
- Other names
- anti-BCMA CAR-T (Hrain)Human Derived anti-BCMA CAR-T InjectionHK10-BCMA-CAR-THK-10-BCMA-CAR-THK 10-BCMA-CAR-T
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on HRC0202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRC0202.